跳转至内容
Merck
CN

主要文件

查看所有文档

S0883

柳氮磺胺吡啶

97.0-101.5%

别名:

2-羟基-5-\ { \ { 4-[（2-吡啶氨基）磺酰基]苯基}偶氮}苯甲酸, 5-[对-(2-吡啶胺磺酰基)苯]偶氮水杨酸, 柳氮磺胺吡啶

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C18H14N4O5S
化学文摘社编号:
599-79-1
分子量:
398.39
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329824182
EC Number:
209-974-3
Beilstein/REAXYS Number:
356241
MDL number:
MFCD00057363
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Segment

200

assay

97.0-101.5%

form

powder

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

260-265 °C (dec.) (lit.)

application(s)

forensics and toxicology
pharmaceutical (small molecule)

mode of action

DNA synthesis | interferes, enzyme | inhibits

SMILES string

OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3

InChI

1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

InChI key

NCEXYHBECQHGNR-QZQOTICOSA-N

Gene Information

human ... ALOX5(240), PTGS1(5742), PTGS2(5743)

General description

柳氮磺胺吡啶(SSZ)属于磺胺类药物，可代谢为5-氨基水杨酸和磺胺吡啶。SSZ是抗菌剂（磺胺吡啶）和消炎剂（水杨酸）的反应产物。
化学结构：磺胺

Application

柳氮磺胺吡啶在临床研究中用作分析标准品：
  • 研究其对多发性硬化症(MS)患者的治疗潜力。
  • 通过抑制试验动物大鼠骨关节炎进展相关的软骨退变和疼痛研究其作为抗关节炎药物的作用。

此外，还可作为分析参考标准，以通过酶联免疫吸附试验(ELISA)和荧光分光度技术量化生物样本和水样中的分析物。



有关合适仪器技术的更多信息，请参考产品的分析证书。如需进一步支持，请联系技术服务。

Still not finding the right product?

Explore all of our products under 柳氮磺胺吡啶

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 2 - Carc. 2 - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 2

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000550131
0000550131
0000478691
0000478691
0000458207

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Maarten Boers et al.
Annals of the rheumatic diseases, 72(3), 406-409 (2012-11-17)
Treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) antagonists changes the relationship between disease activity and progression of radiological joint damage ('disconnect'): patients who have little or no response of disease activity still show reductions in damage progression.
M van den Broek et al.
Clinical and experimental rheumatology, 30(4 Suppl 73), S35-S38 (2012-10-20)
Targeted treatment is effective in the short term in achieving low disease activity or even remission in patients with rheumatoid arthritis (RA). The benefits of long-term targeted treatment are discussed based on the BeSt study results. The BeSt study has
Johan A Karlsson et al.
Annals of the rheumatic diseases, 72(12), 1927-1933 (2012-12-01)
To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ). RA-patients with symptoms <1 year were enrolled between 2002
查看所有相关文献

全球贸易项目编号

货号GTIN
S0883-50G04061833015261
S0883-100G04061833015247
S0883-10G04061836830915